Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Armonia is an injectable, multifractional intercalated cross-linked hyaluronic acid (MIC-HA) specifically designed for the treatment of Genitourinary Syndrome of Menopause (GSM) and vaginal atrophy. Developed by the Italian company Regenyal, it utilizes a proprietary cross-linking process to create a biopolymer that integrates into the vaginal extracellular matrix. Armonia functions by restoring tissue hydration through its high water-binding capacity and reinforcing the structural integrity of the vaginal wall. Beyond its physical properties as a filler, it also bio-stimulates the tissue by interacting with the CD44 receptor, which triggers a regenerative response characterized by increased collagen production, improved vascularization (angiogenesis), and enhanced cellular migration. This combined physical and biological action aims to alleviate symptoms such as vaginal dryness, itching, and dyspareunia, thereby improving sexual function and overall quality of life in postmenopausal women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Armonia.